Last updated on December 2019

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Brief description of study

The primary purpose of the study is to evaluate safety and tolerability and to determine recommended Phase 2 dose (RP2D) of E7389-LF in combination with nivolumab in Phase 1b part, and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in Phase 2 part in each tumor type.

Clinical Study Identifier: NCT04078295

Find a site near you

Start Over

Eisai Trial Site #1

Chuo Ku, Japan
  Connect »